Ethypharm Announces Xavier LASSERRE as the New CCO | Leading Pharmaceutical Veteran

Denis DELVAL, President & CEO of the Ethypharm Group, announces the appointment of Xavier LASSERRE as Chief Commercial Officer (CCO), effective June 12, 2023.

Xavier LASSERRE has a strong experience and expertise in the pharmaceutical industry, particularly in the European markets, both in the retail and hospital sectors.

He holds an advanced degree in Neuroscience and is a graduate of ESCP (Paris Business School). With over 25 years of experience, he has demonstrated remarkable leadership in various roles, contributing significantly to the success and transformation of businesses under his responsibility. Xavier’s most recent position was as Head of Commercial Operations at Zentiva Group, where he was a valued member of the Executive Committee, overseeing affiliate General Managers and export activities.

Xavier joins the Executive Committee of Ethypharm and leads the company’s head of affiliates UK, China, France, Spain, Germany, and Italy. Additionally, Xavier will oversee the distribution and licenses businesses, as well as the Business Development functions.

“I’ am thrilled to join Ethypharm as the new Chief Commercial Officer. Ethypharm has a strong commitment to improving patient lives, and I am eager, with the talented team at Ethypharm, to contribute to the company’s growth and success. I look forward to leading the commercial strategy, driving market expansion, and fostering collaborations to bring our valuable treatments to more patients worldwide.” Says Xavier LASSERRE.

Denis DELVAL – CEO & President of the Group Ethypharm, expresses confidence in Xavier’s ability to drive the company’s commercial growth and stated, “We are delighted to welcome Xavier to the Ethypharm Group. His extensive experience and proven track record in the pharmaceutical industry make him an ideal fit for our organization. We are confident that Xavier’s commercial talent and expertise combined with his leadership will contribute significantly to our continued success. We are excited about this new chapter and look forward to working together towards achieving our goals and further strengthening our position in the market.”

SourceEthypharm

Hot this week

Avery Dennison Medical Introduces Ipdated SilFoam Lite: Sustainability, MDR Certification & Performance Improvements

The newly enhanced SilFoam Lite delivers superior efficiency and reliability, bringing improved fluid handling capabilities and improved tack. These improvements make the product ideal for customers seeking quality, high-performance solutions in wound care notes Avery Dennison Medical.

Voluntary Recall Notifying Medtronic Insulin Pump Users of Potential Risks of Shortened Pump Battery Life

Medtronic plc voluntarily issued a field action starting on July 31, 2024, notifying global customers of its MiniMedâ„¢ 600 series or 700 series insulin pumps to follow their pump's built-in alerts and alarms for battery status and to contact Medtronic if they observe changes in the battery life of their pump

Medtronic Expands AiBLE Spine Surgery Ecosystem with New Technologies and Siemens Healthineers Partnership

New advancements in the AiBLE Spine Surgery ecosystem build upon the company's commitment to procedural innovation and execution

Axlab, Danish Medtech Pioneer, expands to US with Advanced Robotic Tissue Sectioning for Pathology Laboratories

Kris Rokke, National Sales Director for Axlab in the US. "My team and I are extremely excited and honored about this unique opportunity to also offer this advanced technology to labs across the US and thus contribute to the pathology labs of tomorrow."

Spartan Medical Broadens Single-Use Sterile Instrument Portfolio to Improve Outcomes, Increase Efficiency, and Generate Cost Savings

Spartan Medical products portfolio of single-use, sterile med tech includes micro and minor surgical convenience kits, kerrison rongeurs, spinal and general surgical retractors, dural repair kits, synthetic biologics, and a wide range of orthopedic pre-sterilized implants and devices.